CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

All Clinical Trials for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00224549 ↗	PHARES Study: Management of Resistant Hypertension	Completed	Assistance Publique - Hôpitaux de Paris	Phase 4	2005-04-01	The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy.
NCT00515021 ↗	Diurnal Variation of Plasminogen Activator Inhibitor-1	Completed	National Center for Research Resources (NCRR)	Phase 4	2007-04-01	To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
NCT00515021 ↗	Diurnal Variation of Plasminogen Activator Inhibitor-1	Completed	Vanderbilt University Medical Center	Phase 4	2007-04-01	To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration.
NCT00865124 ↗	Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2008-09-01	Aldosterone is a significant mediator of cardiovascular injury associated with heart failure and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those of angiotensin converting enzyme inhibitors or angiotensin II (ANGII) receptor blockers. This study will test the hypothesis that mineralocorticoid receptor (MR) antagonists exert beneficial cardiovascular effects, specifically by decreasing vascular injury and improving vascular function. A randomized, double-blind study will be conducted, in which participants with Type 2 Diabetes Mellitus will undergo a series of assessments to test heart, blood vessel, and kidney function at baseline, and after 2 and 6 months of treatment with one of the following drugs: 1. spironolactone 2. hydrochlorothiazide (HCTZ) plus potassium 3. placebo In the event of insufficient funds, randomization to the placebo arm will be stopped and primary assessment of outcomes will occur at baseline and after 6 months of treatment.

Clinical Trial Conditions for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Condition Name

Condition Name for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Intervention	Trials
Hypertension	4
Acute Kidney Injury	1
Blood Pressure	1
Chronic Kidney Diseases	1

Condition MeSH

Condition MeSH for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Intervention	Trials
Hypertension	4
Nephrotic Syndrome	1
Cardiovascular Diseases	1
Nephrosis	1

Clinical Trial Locations for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Trials by Country

Trials by Country for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Location	Trials
United States	13
China	1
Netherlands	1
Mexico	1
Thailand	1

Trials by US State

Trials by US State for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Location	Trials
Tennessee	2
Texas	1
Massachusetts	1
Virginia	1
Pennsylvania	1

Clinical Trial Progress for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Clinical Trial Phase

Clinical Trial Phase for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	5
Phase 3	1

Clinical Trial Status

Clinical Trial Status for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Clinical Trial Phase	Trials
Completed	5
Recruiting	3
Terminated	1

Clinical Trial Sponsors for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

Sponsor Name

Sponsor Name for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Sponsor	Trials
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	1
National Heart, Lung, and Blood Institute (NHLBI)	1
National Institutes of Health (NIH)	1

Sponsor Type

Sponsor Type for HYDROCHLOROTHIAZIDE; SPIRONOLACTONE
Sponsor	Trials
Other	10
NIH	3
U.S. Fed	2

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE Market Analysis and Financial Projection

Last updated: April 27, 2026

Clinical Trials Update, Market Analysis, and Projection for Hydrochlorothiazide + Spironolactone

What is the current clinical and regulatory status for hydrochlorothiazide plus spironolactone?

Hydrochlorothiazide (HCTZ) and spironolactone are widely used, off-patent medicines with fixed-dose combination products in multiple jurisdictions. There is no single, dominant “new” pivotal clinical development program for the combination comparable to late-stage brand-drug pipelines; instead, clinical activity is largely centered on:

• Guideline-driven use in hypertension and edema populations
• Post-marketing studies and comparative effectiveness research versus alternative antihypertensives/diuretics
• Small to mid-size investigator-initiated trials addressing renal outcomes, electrolyte safety, and real-world adherence

Because the medicines are mature and generic, “trial update” in practice means: ongoing studies are typically incremental and geographically fragmented, and new registrational filings are usually not combination-specific.

Regulatory context (US, at a product level):

• Fixed-dose combinations containing HCTZ and spironolactone have long-standing marketing authorization; clinical trial activity is not typically required to re-establish efficacy for the combination due to legacy data and bioequivalence pathways for generics (where applicable).

What clinical endpoints and safety themes dominate HCTZ + spironolactone studies?

Across the evidence base for the combination (and for each agent class), recurring clinical endpoints and safety themes include:

Efficacy endpoints

• Blood pressure reduction (systolic/diastolic change from baseline; proportion achieving target BP)
• Edema control (weight change, symptom scores, diuresis metrics)

Safety endpoints

• Potassium balance
  • Spironolactone increases serum potassium (hyperkalemia risk in susceptible patients)
  • Thiazide can lower serum potassium (hypokalemia risk)
  • The combination often targets a net balance, but patients with CKD, diabetes, advanced age, or RAAS blockade still require monitoring
• Renal function
  • Serum creatinine and estimated glomerular filtration rate (eGFR)
• Electrolytes
  • Sodium and bicarbonate changes; magnesium effects in some cohorts
• Adverse events profile
  • Gynecomastia and breast pain risk is linked to spironolactone exposure; thiazide-associated metabolic effects (glucose and lipids) can appear in longer follow-up

Typical trial design patterns

• Short-to-mid duration follow-up for BP control and laboratory safety (weeks to months)
• Real-world cohort designs in later-phase observational research (months to years)

Are there ongoing clinical trials that could change market dynamics soon?

For an off-patent, fixed-dose combination like HCTZ + spironolactone, near-term market dynamics typically hinge less on new efficacy breakthroughs and more on:

• Safety label refinements (hyperkalemia risk stratification; renal monitoring language)
• Formulation and access changes (insurance coverage, generics switching, preferred formulary lists)
• Competing diuretic strategies in key indications (RAAS inhibitor optimization, SGLT2 inhibitor standardization, mineralocorticoid receptor antagonist (MRA) alternatives)

No specific, dominant “new registration” program for the combination is expected to materially reset the clinical standard of care on a short horizon, based on how mature the assets are and how generics gain access.

---

Market Analysis: How big is the HCTZ + spironolactone market and what drives it?

What is the market structure?

HCTZ and spironolactone are both widely available as generics in many countries. The combination market tends to behave like a volume-driven, price-competitive segment:

• Generic competition with multiple manufacturers
• Formulary dependency in hypertension and edema
• Therapeutic overlap with other diuretics and MRAs
• Switching behavior between brands and generics driven by reimbursement, local sourcing, and pill burden

What demand drivers matter most?

The combination’s demand is supported by four primary demand channels:

1. Hypertension prevalence and chronic medication adherence
2. Edema and heart failure adjunct use (patient selection varies by region and guideline implementation)
3. Cost sensitivity in payer mix and formularies
4. Perceived safety balance versus pure spironolactone or pure thiazide regimens, with monitoring

Constraints on adoption

• Hyperkalemia and renal impairment screening requirements
• Drug-drug interaction risk in patients on ACE inhibitors, ARBs, direct renin inhibitors, and potassium supplements
• Long-term metabolic monitoring expectations (especially in diabetics and older adults)

How does this market compare with alternative diuretic strategies?

HCTZ + spironolactone competes indirectly with:

• Other thiazide-based regimens (HCTZ or thiazide-like diuretics with/without RAAS agents)
• Loop diuretics for stronger diuresis needs (especially in advanced heart failure)
• Alternative MRAs
  • Eplerenone (often favored for lower endocrine side effects but higher cost historically)
  • Finerenone (in specific CKD/T2D pathways, payer driven)
• SGLT2 inhibitors in modern heart failure and CKD care (diuretic-sparing effect changes how often diuretics are escalated)

In practice, the combination retains a strong foothold where cost, monitoring infrastructure, and guideline habits align.

---

Projection: What is the 2025-2035 outlook for HCTZ + spironolactone?

How should you model growth for an off-patent combination?

For mature fixed-dose combinations, market projection typically follows:

• Underlying disease pool growth (population aging and hypertension incidence prevalence)
• Volume stability (limited incremental patient acquisition in treated segments)
• Price erosion (generic price pressure)
• Share shifts driven by guideline preference and safety perceptions

For HCTZ + spironolactone, the most realistic projection pattern is:

• Low single-digit volume growth
• Flat-to-declining unit pricing
• Revenue growth that can be modest even when volume rises

Base-case projection (framework)

Given the typical behavior of off-patent generic combinations, a reasonable base-case projection for 2025 to 2035 is:

• Volume: modest growth tied to chronic disease management and persistently high hypertension prevalence
• Revenue: constrained by ongoing generic price competition and competitive substitution toward alternative MRAs and modern heart failure/CKD regimens

Outcome expectation

• The combination is likely to remain a stable, high-volume therapy in markets that support generic access and sustained antihypertensive prescribing.
• Major upside depends more on reimbursement and local formulary decisions than on new clinical breakthroughs.

---

Competitive Landscape: Who controls demand and why?

What competition exists at product and strategy levels?

Competition comes from two angles:

1) Product-level generic competitors

• Multiple manufacturers across dosage strengths and package formats
• Switching driven by tendering, pharmacy contracting, and payer preferred lists

2) Therapy-level alternatives

• Preferred thiazide-like diuretics (regional preference varies)
• MRAs other than spironolactone (especially where endocrine adverse events become a switching lever)
• RAAS-optimized and SGLT2-backed regimens that can reduce escalation to MRA+thiazide combinations

Where does prescribing stay sticky?

Prescribers often stick with HCTZ + spironolactone when:

• Patients need a combination diuretic effect with a manageable endocrine profile relative to higher-dose spironolactone use
• Monitoring pathways for potassium and renal function are established
• Local pricing makes it the easiest reimbursement choice

---

Key Takeaways

• Hydrochlorothiazide + spironolactone is a mature, off-patent fixed-dose combination with clinical evidence dominated by chronic use, post-marketing safety themes, and guideline-driven application rather than late-stage registrational breakthroughs.
• Ongoing clinical activity is most likely to focus on electrolyte and renal safety, BP control outcomes, and real-world adherence and monitoring.
• Market growth is constrained by generic price pressure but supported by steady chronic disease demand; the most probable pattern from 2025 to 2035 is modest volume growth with limited revenue upside.
• Competitive substitution will increasingly come from therapy-level shifts (alternative MRAs and modern HF/CKD care patterns) and from formulary dynamics.

---

FAQs

1. Is hydrochlorothiazide plus spironolactone still clinically relevant in hypertension?
   Yes. It remains used in selected patients where combination diuretic effects and potassium balance are appropriate with monitoring.

2. What is the main safety risk with the combination?
   Hyperkalemia risk in susceptible populations, alongside standard diuretic electrolyte monitoring needs.

3. Do new large clinical trials usually drive this combination’s market growth?
   Typically not. Market changes are usually driven by generics access, formulary placement, and incremental safety/real-world effectiveness evidence.

4. How does competition from other MRAs affect demand?
   It can shift share, particularly where endocrine side effects or reimbursement patterns favor alternative MRAs.

5. What variables matter most for revenue projection in off-patent combinations?
   Unit price trends, volume persistence, formulary/tender dynamics, and substitution away from older diuretic strategies.

---

References (APA)

[1] FDA. (n.d.). Drugs@FDA database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization. (n.d.). Guidelines for the management of hypertension. World Health Organization. https://www.who.int/
[3] American Heart Association. (n.d.). Hypertension clinical guidance and scientific statements. American Heart Association. https://www.heart.org/
[4] National Kidney Foundation. (n.d.). Clinical guidance on CKD and mineral metabolism. National Kidney Foundation. https://www.kidney.org/
[5] GBD Results Tool. (n.d.). Global burden of disease estimates for hypertension. Institute for Health Metrics and Evaluation. https://ghdx.healthdata.org/gbd-results-tool